Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...

Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...

Q3 2024 Earnings Call Transcript October 31, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday.

In late September, the FDA approved xanomeline and trospium chloride (Cobenfy) for schizophrenia in adults, the first new ...

Bristol Myers Squibb reported strong third-quarter financial results, notching an 18% jump in its growth portfolio.

1 Cobenfy (xanomeline and trospium chloride) has a new mechanism of action, and there is a lot of potential for this drug in treating patients with schizophrenia, said Megan Ehret, PharmD ...

got Food and Drug Administration approval for one of the first new schizophrenia treatments in decades. Karuna had been founded by PureTech Health and spun out into its own company, before being ...

Seaport plans to use the new funds to push forward its pipeline of experimental drugs, including its most advanced ... but once resolved, was approved Cobenfy (formerly KarXT) for schizophrenia.

SINGAPORE – Newer drugs within a class originally developed ... diabetes-induced kidney failure rates in the world, with six new cases diagnosed every day. The National Kidney Foundation ...